-
FDA calls for warning labels on commercial CAR-T therapies amid cancer probe
The FDA is now calling for warning labels on all commercial CAR-T therapy products amid its investigation into 22 reports about a possible being linked to lymphoma. -
Corrections made in ongoing FDA eye drop recall
The FDA has published corrections and additions to a company's voluntary recall of eye drops after a wave of several others throughout 2023. -
Washington pharmacists prepare to prescribe abortion pills
A handful of pharmacists in Washington state are training to prescribe the abortion medication mifepristone, NPR reported Jan. 22. -
Maryland system reduces opioid scripts by 55%
Over the last five years, Hagerstown, Md.-based Meritus Health cut the number of opiates prescribed by more than 55% in its effort to quell the national opioid epidemic. -
Drug shortages group elects 3 pharmacy leaders to board
The End Drug Shortages Alliance appointed Terri Lyle Wilson as its new chair and appointed two board members Jan. 23. -
North Carolina state health plan drops weight loss drug coverage; to incur $54M rebate loss
North Carolina's state health plan dropped new coverage for weight loss drugs Jan. 1, a decision that is expected to cost the state $54 million in lost drug rebates, WRAL News reported Jan. 12. -
Some BCBS plans cover new sickle cell gene therapies
Some Blue Cross Blue Shield companies now cover two newly approved sickle cell gene therapies, which cost about $2 million and $3 million per dose. -
FDA finds deficiencies at Eli Lilly plant: Reuters
During a visit last summer, FDA inspectors flagged eight deficiencies at an Eli Lilly manufacturing plant in Branchburg, N.J., according to an inspection report Reuters obtained through a Freedom of Information Act Request. -
Drugmakers explore muscle loss prevention when taking weight loss drugs
Despite their rise to popularity as solutions for weight loss, drugs like Ozempic and Wegovy can also lead to muscle loss, and now pharmaceutical companies are looking at ways to curb the unwanted side effect, according to The Wall Street Journal. -
'Faux-zempic': What to know about compounded weight loss drugs
Physicians, drugmakers, obesity organizations and the FDA are fretting about compounded versions of popular weight loss and diabetes drugs, including Wegovy, Ozempic and Zepbound. -
Children's National Hospital taps Clearway to deliver $2.8M gene therapy
Washington, D.C.-based Children's National Hospital administered Zynteglo, a $2.8 million gene therapy, to its first pediatric patient with the help of Clearway Health. -
FDA adds severe risk warning to bone disease drug
The bone disease drug Prolia has a new boxed warning, the FDA's most prominent warning, because of an increased risk of severe hypocalcemia among chronic kidney disease patients. -
Nitrosamine measures might disrupt anesthetic supply, Dr. Eric Tichy says
Hospitals should start conserving supply of short-term anesthetics as drug manufacturers become more conservative with nitrosamine measures, according to Eric Tichy, PharmD. -
Pharmacist becomes Philadelphia hospital CEO
Former health system pharmacy leader Shawn Parekh, PharmD, recently became CEO of a Philadelphia hospital. -
UHS pharmacies work around payment issue
United Health Services' pharmacies are managing an issue with processing health savings account and flexible spending account debit card payments, the Binghamton, N.Y.-based system said. -
Ozempic, Mounjaro become pricier
Type 2 diabetes drugs Ozempic and Mounjaro are among the 775 brand-name drugs with higher prices in 2024, The Wall Street Journal reported Jan. 18. -
Drug cost trends in 2024 are 'nearly unprecedented,' research finds
Drugmakers aren't raising prices like they used to, according to data from 46brooklyn Research. -
FDA clears CRISPR therapy for 2nd disease
The FDA on Jan. 16 approved Casgevy to be used as a treatment for beta-thalassemia. The move comes just over a month after the nation's first medicine based on CRISPR gene-editing technology was approved to treat patients with sickle cell disease. -
How to develop a staph vaccine when 'the rules are different'
After multiple failed attempts at developing a vaccine against one of the most common infections, Staphylococcus aureus, researchers at the University of California San Diego have suggestions about how to fix the problem. -
Florida's plan to import drugs: 5 things to know
On Jan. 5, Florida became the first state approved by the FDA to import cheaper medicines from Canada, but the plan is facing backlash from experts in Canada and the U.S.
Page 13 of 50